Back to Search
Start Over
Beneficial Effect of Upadacitinib in a Refractory Course of Scleritis: A Case Report.
- Source :
- Ocular Immunology & Inflammation; Aug2024, Vol. 32 Issue 6, p1076-1078, 3p
- Publication Year :
- 2024
-
Abstract
- Noninfectious scleritis typically takes a chronic course, and systemic corticosteroids or disease-modifying anti-rheumatic drug (DMARD) treatment may be inevitable for a prolonged period. Janus kinase (JAK) inhibitors are a relatively new therapeutic option for inflammatory diseases, and three cases of successful treatment of scleritis with tofacitinib, a substance targeting JAK-1 and -3, have been published up to now. We here describe the case of a 51-years-old female patient with bilateral anterior and posterior scleritis who, after treatment failure of multiple DMARDs, finally achieved clinical quiescence of disease under treatment with upadacitinib, a selective JAK-1 inhibitor. [ABSTRACT FROM AUTHOR]
- Subjects :
- SCLERITIS
THERAPEUTICS
TREATMENT failure
TREATMENT effectiveness
KINASE inhibitors
Subjects
Details
- Language :
- English
- ISSN :
- 09273948
- Volume :
- 32
- Issue :
- 6
- Database :
- Complementary Index
- Journal :
- Ocular Immunology & Inflammation
- Publication Type :
- Academic Journal
- Accession number :
- 178854922
- Full Text :
- https://doi.org/10.1080/09273948.2022.2145488